FDA warning letters are up 156% since 2020, and 79% of them cite data integrity. Clinical trial data must be retained for 15+ years. Post-quantum signatures make sure every lab result, every chain of custody record, and every temperature log is still legally valid in 2040.
Warning letters have reached record levels. ECDSA, the signature scheme protecting your trial data right now, won't survive the decade.
FDA warning letters are up 156% since 2020. Of those citing data integrity violations, 79% name it as the main cause, not just a side issue.
Clinical trial data must be retained 15+ years. ECDSA signatures, which protect most eTMF/EDC systems today, are projected to be breakable by quantum computers by 2035.
The average FDA 483 observation takes more than 3 years to resolve, with $500M+ in delayed approvals. All of it traces back to data integrity failures that could have been prevented.
GENESIS attaches ML-DSA-65 + Ed25519 dual-signed receipts to the clinical data that must survive regulatory scrutiny in 2040.
Every test result, whether it is a CBC, a metabolic panel, or a biomarker assay, gets an ML-DSA-65 + Ed25519 signed receipt with the subject ID, timestamp, lab operator, and instrument identifier baked in.
ML-DSA-65 + Ed25519Every sample handoff is logged with cryptography, from collection to analysis. Each transfer event creates a signed receipt linking the collector, handler, recipient, time, and condition.
custody_chain · signed transferTemperature sensor readings from −80°C freezers, liquid nitrogen storage, and shipping containers generate signed receipts at configurable intervals. Excursions are flagged immutably.
IoT sensors · excursion logging21 CFR Part 11 requires electronic audit trails for any regulated record. GENESIS builds ALCOA+-compliant audit trails automatically. Every entry is attributable, timestamped, and original.
21 CFR Part 11 · ALCOA+Post-quantum ML-DSA-65 (FIPS 204) signatures remain valid through the quantum transition. Data signed in 2025 will be legally defensible in 2040 when your 15-year retention window closes.
FIPS 204 · 2040+ validOne click exports a signed ZIP with the complete regulatory submission package: all receipts, audit trails, and verification keys, ready for court out of the box.
signed ZIP · court-admissibleThe FDA's ALCOA+ framework defines what makes clinical data trustworthy. GENESIS meets each principle through cryptography, not just policy.
Every signed receipt embeds the cryptographic identity of the operator, instrument, and system that generated the data. Attribution cannot be forged or removed.
Receipts are structured JSON with a verification path anyone can read. Any regulator with an open-source verifier can read and check it. No proprietary software needed.
GENESIS signs records at the moment they are captured, with a hardware-backed timestamp. Backdating is impossible because the signature locks in the exact moment of creation.
The original signed receipt never changes. Any later amendment creates a new signed record that points back to the original, so the chain of custody is never broken.
Instrument readings are signed at the sensor level before any software touches them. The signed receipt holds the raw measurement, so nobody can quietly change it along the way.
GENESIS enforces completeness rules: every required field has to be filled in before a receipt can be signed. Incomplete records get rejected automatically.
All sites in a multi-center trial use the same cryptographic schema. Receipt format, signing key hierarchy, and verification process are identical across every CRO and laboratory.
ML-DSA-65 (FIPS 204) is NIST's post-quantum standard. Receipts signed today remain cryptographically verifiable after ECDSA is deprecated and quantum computers are mainstream.
Receipts are self-contained portable documents. You don't need any Hive infrastructure to check them. Any regulator or court can verify any receipt offline, at any time, anywhere.
Clinical trial data outlives the cryptography protecting it. Here is the timeline, and why you can't afford to wait.
A drug trial submitted to the FDA in 2025 may be reviewed, litigated, or audited in 2042. The signatures on that data need to be valid for the entire window. ECDSA will not be.
Most eTMF and EDC systems use ECDSA-256 or RSA-2048 to sign clinical records. These algorithms work fine today, but the clock is running.
Vulnerable if not upgradedNIST's post-quantum migration timeline calls for phasing out ECDSA for anything that needs signatures valid for more than 5 to 7 years. Regulatory guidance will follow.
NIST SP 800-131A Rev. 3Multiple intelligence agencies and national labs project cryptographically-relevant quantum computers (CRQCs) by the early 2030s. Shor's algorithm breaks ECDSA and RSA at scale.
Harvest now, decrypt later attacks activeA Phase III trial that started in 2025 reaches the end of its required retention period. Any data signed with ECDSA back in 2025 may no longer be verifiable, which creates serious regulatory exposure.
21 CFR Part 312.62 · ICH E6(R3)GENESIS applies NIST's finalized post-quantum digital signature standard the moment data is captured. Every receipt is signed with ML-DSA-65, the algorithm built to survive the move from classical to quantum computing.
FIPS 204 · ML-DSA-65 · Valid 2025 to 2045+GENESIS sits alongside your existing EDC, eTMF, and CTMS infrastructure. It doesn't replace it. CRO partners can deploy in days, not quarters.
GENESIS is built to run alongside the clinical operations platforms your CRO already uses. IQVIA, Parexel, and Covance partners can onboard through a pre-certified connector, with no custom development needed.
GENESIS runs as a sidecar process alongside your existing Electronic Data Capture and Trial Master File systems. Data events flow through a signing layer before storage, with zero changes to your existing workflows.
Zero workflow disruption Sidecar · not a replacementGENESIS integrates with the leading clinical data platforms through API-level connectors. No custom middleware, no proprietary hardware requirements.
When an FDA 483 observation arrives or a regulatory submission is due, GENESIS generates a signed ZIP with every relevant receipt, audit trail, and verification key, ready for submission or litigation.
One-click signed ZIPHere's how paper records, standalone eTMF/EDC systems, and GENESIS stack up on the capabilities regulators and courts actually check.
| Capability | Paper + Manual | eTMF / EDC Only | GENESIS |
|---|---|---|---|
| Post-quantum signatures | N/A | ECDSA only | ML-DSA-65 (FIPS 204) |
| Offline verification | Manual review required | Vendor system required | Self-contained, no dependency |
| ALCOA+ compliant | Process-dependent | Partial: no crypto proof | Cryptographically enforced |
| FDA 483 defense | Weak: paper trail gaps | Partial: audit logs only | Signed receipts, court-admissible |
| 15-year integrity | Degradation risk | ECDSA breaks by 2035 | Valid through 2040+ |
| Court-admissible | Variable: jurisdiction risk | Depends on vendor | Signed ZIP, open verifier |
| 21 CFR Part 11 | Manual compliance | System-level only | Built-in, per-record |
| Cold chain signing | Paper logs | Not available | IoT sensor receipts |
GENESIS is currently accepting pilot partners. That means pharma companies with recent FDA 483 observations for data integrity, or CROs preparing Phase III submissions with 10+ year retention requirements.
Patent Pending · 21 CFR Part 11 · ALCOA+ · FIPS 204 · ML-DSA-65